No Data
No Data
Immatics Is Maintained at Buy by Mizuho
Immatics Is Maintained at Buy by Mizuho
Express News | Mizuho Maintains Buy on Immatics, Raises Price Target to $16
Immatics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 44.4% Mizuho $14 → $16 Maintains Buy 11/02/2023 — Cantor Fitzgerald Initiates Coverage On → Ov
Buy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising Outlook
Express News | Immatics NV : Mizuho Raises Target Price to $16 From $14
Nearly 90% of patients have shrinking tumors! Immatics (IMTX.US) innovative cell therapy phase 2/3 trial is about to begin
iMA203 is a TCR-T cell developed by IMMatics' proprietary ActenGine platform and targets the melanoma antigen PRAME presented by HLA-A*02.